Drug that starves tumors shows promise against advanced kidney cancer

NCT ID NCT00403169

Completed Disease control Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase II trial tests the drug lenalidomide (CC-5013) in people with advanced or inoperable kidney cancer. Lenalidomide works by cutting off blood flow to tumors, which may stop or slow their growth. The study aims to see how many patients respond to treatment and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide (also called CC-5013)
What this could lead to: If it works, lenalidomide could offer a new treatment option for people with advanced kidney cancer that cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. Lenalidomide can cause serious side effects, and the cancer may still grow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY CANCER

Contacts and locations

Locations

Case Comprehensive Cancer Center

Cleveland, Ohio, 44106-5065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.